查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
支气管镜市场 - COVID-19 的增长、趋势、影响和预测 (2023-2028)
市场调查报告书
商品编码
1190157

支气管镜市场 - COVID-19 的增长、趋势、影响和预测 (2023-2028)

Bronchoscope Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 115 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

在预测期内，支气管镜市场预计将以 7.2% 的复合年增长率增长。

支气管镜在 COVID-19 及相关疾病检测中的应用对市场增长产生了积极影响。 COVID-19引起的肺炎很可能导致低氧血症和呼吸衰竭，需要支气管镜检查。 例如，根据欧洲呼吸学会 2021 年 4 月发表的一篇论文，通过支气管镜清除粘液栓和支气管内凝块并解决 COVID-19 重症患者的肺不张导致机械通气可以得到改善。 此外，根据 Ambu A/S 2021/22 年年度报告，由于 2020/21 年比较高的市场库存和竞争加剧（尤其是在美国市场）带来的高市场库存，支气管镜行业正面临挑战。说他做到了。 全球支气管镜业务销售额增长了 70%，反映了从可重复使用的内窥镜向一次性设备的转变，儘管与 COVID-19 之前相比有所下降。 因此，总体而言，可以说自 COVID-19 大流行以来对支气管镜市场产生了重大影响。

呼吸系统疾病和肺癌负担的增加、医院对支气管镜检查设施投资的增加以及技术进步预计将推动支气管镜检查市场。 例如，根据美国癌症协会 2022，肺癌（包括小细胞和非小细胞）是美国男性和女性中第二大最常见的癌症。 此外，根据 2022 年国际呼吸学会论坛报告，估计约有 2 亿人患有慢性阻塞性肺病，2.62 亿人患有哮喘。 此类呼吸系统疾病的高患病率和癌症患者数量的增加预计将增加对用于诊断该疾病的支气管镜的需求，最终推动市场。

此外，市场参与者频繁推出新产品并在各自细分市场采取不同的增长策略，这有望推动市场增长。 例如，2021 年 4 月，奥林巴斯宣布推出公司首款一次性支气管镜 H-SteriScopes，从而扩大其呼吸产品组合。 奥林巴斯全资子公司维兰医疗与湖南华信医疗强强联手，推出H-SteriScope系列产品。 此外，2021 年 5 月，PENTAX Medical Europe 的新型一次性支气管镜 PENTAX Medical ONE Pulmo 获得了 CE 标誌。 这种创新产品可在不影响肺部护理的情况下提供高质量护理。 PENTAX Medical ONE Pulmo 是一款一次性支气管镜，具有出色的吸力和高清图像质量。 因此，上述因素正在影响气管镜市场的增长。 然而，预计与支气管镜检查程序相关的高额管理费用将阻碍预测期内的市场增长。

主要市场趋势

一次性支气管镜有望在预测期内快速增长。

与可重复使用的支气管镜相比，ICU 和围手术期麻醉师使用的一次性支气管镜具有可接受的性能水平，并且由于无菌而降低感染风险具有明显优势。 一次性使用的支气管镜消除了与可重复使用的支气管镜的交叉污染，并且在某些临床环境中更具成本效益。 它们有助于检测肿瘤、慢性阻塞性肺病、肺癌和许多其他疾病。 例如，国家医学图书馆于 2022 年 1 月发表的一项研究发现，在支气管镜检查和重症监护病房的某些情况下，使用一次性支气管镜优于可重复使用的支气管镜可提高便携性，它受益于即时可用性和理论上较低的临床相关感染风险。 此外，根据国家医学图书馆 2022 年 1 月发表的一篇论文，一次性支气管镜被认为是可重复使用的，仅考虑在典型的 ICU 环境中支气管镜交叉污染和随后感染的可能性。据说成本更高-比支气管镜检查有效。 因此，一次性支气管镜相对于可重复使用支气管镜的上述优势有望推动该领域的增长。

此外，主要市场参与者的技术产品进步预计将推动该细分市场的增长。 例如，2021 年 8 月，波士顿科学公司的 EXALT B 型一次性支气管镜获得了美国 FDA 510(k) 许可，该镜设计用于重症监护病房 (ICU) 和手术室的床边手术。我得到了 预计这些进步将在预测期内推动市场增长。 因此，所有上述因素预计将在预测期内推动分部增长。

预计在预测期内北美将主导支气管镜市场

由于支气管镜检查程序的数量不断增加以及慢性阻塞性肺病、肺炎和肺癌等呼吸系统疾病的高发率，预计北美将在支气管镜检查市场占据很大的市场份额。 例如，根据 NCBI 2021 年 6 月的一份报告，美国每年大约进行 500,000 次支气管镜手术。 此外，根据 ACS 的数据，预计 2022 年美国将诊断出的肺癌病例估计约为 236,740 例新病例。 同样，根据加拿大癌症协会的数据，预计到 2022 年加拿大将新增约 30,000 例肺癌病例。 这导致了研究市场的增长，因为北美对支气管镜的需求很高，表明该地区肺癌的负担。 因此，有望推动支气管镜的市场增长。

此外，新产品的推出也将有利于整个细分市场在预测期内的增长。 例如，2021 年 7 月，Verathon 将推出 GlideScope BFlex 一次性支气管镜，它提供一次性支气管镜的可访问性，同时提供通常与可重复使用的支气管镜相关的图像和控制。 预计这种区域进步将促进市场的增长。 因此，由于上述因素，预计北美地区的市场将在预测期内增长。

竞争格局

由于多家公司在全球和区域运营，因此支气管镜市场本质上是分散的。 竞争格局包括拥有市场份额的知名国际企业，如 Teleflex Inc.、Karl Storz GmbH、Olympus Corporation、Lymol Medical、Fujifilm Holdings Corporation、Broncus Medical Inc、Novatech SA、Boston Scientific Corporation、Pentax Medical、Ambu A/S . 和国内公司的分析。

其他好处

  • Excel 格式的市场预测 (ME) 表
  • 3 个月的分析师支持

内容

第一章介绍

  • 研究假设和市场定义
  • 调查范围

第二章研究方法论

第 3 章执行摘要

第四章市场动态

  • 市场概览
  • 市场驱动因素
    • 呼吸系统疾病和肺癌的负担不断增加
    • 增加医院对支气管镜检查设施的投资
    • 技术进步
  • 市场製约因素
    • 支气管镜检查费用高昂
  • 波特的五力分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分（基于价值的市场规模 - 百万美元）

  • 按产品类型
    • 刚性
    • 灵活
    • 配饰
  • 通过使用
    • 一次性型
    • 可重复使用类型
  • 按地区
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东和非洲
      • 海湾合作委员会
      • 南非
      • 其他中东地区
    • 南美洲地区
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章竞争格局

  • 公司简介
    • Ambu A/S
    • Boston Scientific Corporation
    • Broncus Medical Inc.
    • Fujifilm Holdings Corporation
    • Karl Storz GmbH
    • Lymol Medical
    • Novatech SA
    • Olympus Corporation
    • Pentax Medical
    • Teleflex Inc.

第7章 市场机会今后动向

简介目录
Product Code: 68148

The bronchoscope market is expected to register a CAGR of 7.2% over the forecast period.

The application of a bronchoscope for the examination of COVID-19 and associated diseases has positively impacted the growth of the market. Pneumonia caused by COVID-19 was likely to cause hypoxemia and respiratory failure, necessitating a bronchoscope for the examination. For instance, as per an article published by the European Respiratory Society, in April 2021, in critically ill patients with COVID-19, bronchoscopy allows the removal of mucus plugs and intrabronchial clots, and the resolution of atelectasis, thereby improving mechanical ventilation. Furthermore, according to Ambu A/S annual report, 2021/22, the bronchoscopy industry experienced challenges as a result of high market inventories and greater competition, particularly in the American market, brought on by the high comparative from 2020/21. Despite the year's lower performance compared to pre- COVID-19, bronchoscopy business revenue worldwide increased by 70%, indicating the switch from reusable endoscopy to single-use equipment. Therefore, overall, the COVID-19 pandemic had a profound impact on the bronchoscope market since during the pandemic.

The growing burden of respiratory diseases and lung cancer, growing hospital investment in bronchoscopy facilities, and technological advancements are expected to drive the bronchoscope market. For instance, as per the American Cancer Society 2022, lung cancer (both small cell and non-small cell) is the second most common cancer in both men and women in United States. Furthermore, according to the Forum of International Respiratory Societies report 2022, approximately 200 million people are estimated to have COPD, and 262 million people are affected by Asthma. With such a high prevalence of respiratory disease and a rise in cancer cases, the demand for bronchoscopes is expected to increase for the diagnosis of this disease eventually driving the market.

Moreover, market players are frequently launching new products and adopting various growth strategies in their respective segments, which is likely to drive market growth. For instance, in April 2021, Olympus announced the expansion of its respiratory portfolio with the launch of our first line of single-use bronchoscopes, the H-SteriScopes. Veran Medical Technologies, Inc., a wholly owned Olympus subsidiary, and Hunan Vathin Medical Instrument Co., Ltd. worked together to launch the H-SteriScope range. Additionally, in May 2021, PENTAX Medical Europe, has obtained a CE mark for its new single-use bronchoscope - the PENTAX Medical ONE Pulmo. This innovative product provides high-quality care without compromising pulmonary care. The PENTAX Medical ONE Pulmo is a single-use bronchoscope with superior suction power and HD image quality. Thus, the abovementioned factors are impacting the market growth of over the bronchoscope market. However, the high overhead cost of bronchoscopy procedures is expected to hinder market growth over the forecast period.

Key Market Trends

Single Use Bronchoscope Segment is Expected to Witness High Growth Over the Forecast Period

The single-use flexible bronchoscope is used by anesthetists in an ICU or peri-operative setting where they perform to an acceptable level in comparison to reusable flexible bronchoscopes combined with the distinct advantage of a reduced risk of infection owing to their sterility. Single-use flexible bronchoscopes eliminate cross-contamination from reusable bronchoscopes and are cost-effective in several clinical settings. These are helpful for the detection of diseases like tumors, COPD, cancer of the lungs, and many more. For instance, according to the study published by the National Library of Medicine, in January 2022, in certain circumstances in the bronchoscopy and intensive care units, using a single-use bronchoscope over a reusable bronchoscope confers an advantage due to its portability, immediate availability, and theoretically lower risk of clinically relevant infections. Furthermore, according to an article published by the National Library of Medicine, in January 2022, a single-use flexible bronchoscope is cost-effective when solely looking at cross-contamination and possible subsequent infections with bronchoscopes in a typical ICU setting compared with reusable flexible bronchoscope. Thus, the above benefits of a single-use bronchoscope over the reusable bronchoscope are expected to boost segment growth.

Furthermore, the technological product advancements by significant market players are expected to boost segment growth. For instance, in August 2021, Boston Scientific Corporation received U.S. FDA 510(k) clearance for the EXALT Model B Single-Use Bronchoscope, designed for use in bedside procedures within the intensive care unit (ICU) and operating room. Such advancement is expected to drive the growth of the market over the forecast period. Thus, all aforementioned factors are expected to boost segment growth over the forecast period.

North America is Expected to Dominate the Bronchoscope Market Over the Forecast Period

North America is expected to hold a significant market share in the bronchoscope market due to the increasing number of bronchoscopy procedures and higher prevalence rates of respiratory diseases such as COPD, pneumonia, and lung cancer. For instance, according to the NCBI report of June 2021, around 500 thousand procedures of bronchoscopies are performed in United States every year. Furthermore, as per ACS, the estimated number of lung cancer expected to be diagnosed in United States in 2022 is about 236,740 new cases. Similarly, according to the Canadian Cancer Society, about 30,0000 new cases of lung cancer are estimated to be recorded in Canada in 2022. This indicates the burden of lung cancer in the region, which results in the growth of the market studied as there is a high demand for bronchoscopes in North America. Hence, it is expected to boost the bronchoscope market growth.

Additionally, new product launches will also favor the overall segment growth over the forecast period. For instance, in July 2021, Verathon launched the GlideScope BFlex single-use bronchoscope which provides the accessibility of a single-use bronchoscope while delivering the images and control typically associated with a reusable bronchoscope. Such regional advancement is expected to boost the market growth. Thus, owing to the abovementioned factors, the studied market in the North American region is expected to project growth over the forecast period.

Competitive Landscape

The bronchoscope market is fragmented in nature due to the presence of several companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international as well as local companies which hold market shares and are well known including Teleflex Inc., Karl Storz GmbH, Olympus Corporation, Lymol Medical, Fujifilm Holdings Corporation, Broncus Medical Inc, Novatech SA, Boston Scientific Corporation, Pentax Medical, and Ambu A/S, among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Burden of Respiratory Diseases and Lung Cancer
    • 4.2.2 Growing Hospital Investment in Bronchoscopy Facility
    • 4.2.3 Technological Advancements
  • 4.3 Market Restraints
    • 4.3.1 High Overhead Cost of Bronchoscopy Procedure
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD Million)

  • 5.1 By Product Type
    • 5.1.1 Rigid
    • 5.1.2 Flexible
    • 5.1.3 Accessories
  • 5.2 By Usage
    • 5.2.1 Single Use Bronchoscope
    • 5.2.2 Reusable Bronchoscope
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Ambu A/S
    • 6.1.2 Boston Scientific Corporation
    • 6.1.3 Broncus Medical Inc.
    • 6.1.4 Fujifilm Holdings Corporation
    • 6.1.5 Karl Storz GmbH
    • 6.1.6 Lymol Medical
    • 6.1.7 Novatech SA
    • 6.1.8 Olympus Corporation
    • 6.1.9 Pentax Medical
    • 6.1.10 Teleflex Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS